Selected research
Industry Research
Dendritic Cell Cancer Vaccine Immunotherapy Industry Research Report 2026
Market perspective
The global Dendritic Cell Cancer Vaccine Immunotherapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Dendritic Cell Cancer Vaccine Immunotherapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Dendritic Cell Cancer Vaccine Immunotherapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Dendritic Cell Cancer Vaccine Immunotherapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Dendritic Cell Cancer Vaccine Immunotherapy include AVAX Technologies, DCPrime, Gradalis, Heat Biologics, Immunicum, ImmunoCellular Therapeutics, Lineage Cell Therapeutics, MolecuVax and Northwest Biotherapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Dendritic Cell Cancer Vaccine Immunotherapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dendritic Cell Cancer Vaccine Immunotherapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dendritic Cell Cancer Vaccine Immunotherapy Market by Company
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
Immunicum
ImmunoCellular Therapeutics
Lineage Cell Therapeutics
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma
Dendritic Cell Cancer Vaccine Immunotherapy Segment by Type
Provenge
CreaVax
Apceden
Others
Dendritic Cell Cancer Vaccine Immunotherapy Segment by Application
Pediatrics
Adults
Dendritic Cell Cancer Vaccine Immunotherapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dendritic Cell Cancer Vaccine Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dendritic Cell Cancer Vaccine Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dendritic Cell Cancer Vaccine Immunotherapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dendritic Cell Cancer Vaccine Immunotherapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Provenge
- CreaVax
- Apceden
- Others
Applications
- Pediatrics
- Adults
Companies covered
- AVAX Technologies
- DCPrime
- Gradalis
- Heat Biologics
- Immunicum
- ImmunoCellular Therapeutics
- Lineage Cell Therapeutics
- MolecuVax
- Northwest Biotherapeutics
- Pique Therapeutics
- Regeneus
- Tessa Therapeutics
- Vaccinogen
- XEME Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dendritic Cell Cancer Vaccine Immunotherapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Provenge
- 2.2.3 CreaVax
- 2.2.4 Apceden
- 2.2.5 Others
- 2.3 Dendritic Cell Cancer Vaccine Immunotherapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pediatrics
- 2.3.3 Adults
- 2.4 Assumptions and Limitations
3 Dendritic Cell Cancer Vaccine Immunotherapy Breakdown Data by Type
- 3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2021-2026)
- 3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2027-2032)
4 Dendritic Cell Cancer Vaccine Immunotherapy Breakdown Data by Application
- 4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2021-2026)
- 4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2021-2032)
- 5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Region
- 5.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2021-2026)
- 5.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2027-2032)
- 5.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics
- 5.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
- 5.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
- 5.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
- 5.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue
- 6.1.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue (2021-2026)
- 6.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy Head Office and Area Served
- 6.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Players, Product Type & Application
- 6.5 Global Dendritic Cell Cancer Vaccine Immunotherapy Manufacturers Established Date
- 6.6 Global Dendritic Cell Cancer Vaccine Immunotherapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
- 7.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
- 7.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
- 8.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
- 8.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
- 9.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
- 10.2 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
- 10.4 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
- 11.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AVAX Technologies
- 12.1.1 AVAX Technologies Company Information
- 12.1.2 AVAX Technologies Business Overview
- 12.1.3 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.1.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.1.5 AVAX Technologies Recent Developments
- 12.2 DCPrime
- 12.2.1 DCPrime Company Information
- 12.2.2 DCPrime Business Overview
- 12.2.3 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.2.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.2.5 DCPrime Recent Developments
- 12.3 Gradalis
- 12.3.1 Gradalis Company Information
- 12.3.2 Gradalis Business Overview
- 12.3.3 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.3.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.3.5 Gradalis Recent Developments
- 12.4 Heat Biologics
- 12.4.1 Heat Biologics Company Information
- 12.4.2 Heat Biologics Business Overview
- 12.4.3 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.4.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.4.5 Heat Biologics Recent Developments
- 12.5 Immunicum
- 12.5.1 Immunicum Company Information
- 12.5.2 Immunicum Business Overview
- 12.5.3 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.5.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.5.5 Immunicum Recent Developments
- 12.6 ImmunoCellular Therapeutics
- 12.6.1 ImmunoCellular Therapeutics Company Information
- 12.6.2 ImmunoCellular Therapeutics Business Overview
- 12.6.3 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.6.5 ImmunoCellular Therapeutics Recent Developments
- 12.7 Lineage Cell Therapeutics
- 12.7.1 Lineage Cell Therapeutics Company Information
- 12.7.2 Lineage Cell Therapeutics Business Overview
- 12.7.3 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.7.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.7.5 Lineage Cell Therapeutics Recent Developments
- 12.8 MolecuVax
- 12.8.1 MolecuVax Company Information
- 12.8.2 MolecuVax Business Overview
- 12.8.3 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.8.5 MolecuVax Recent Developments
- 12.9 Northwest Biotherapeutics
- 12.9.1 Northwest Biotherapeutics Company Information
- 12.9.2 Northwest Biotherapeutics Business Overview
- 12.9.3 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.9.5 Northwest Biotherapeutics Recent Developments
- 12.10 Pique Therapeutics
- 12.10.1 Pique Therapeutics Company Information
- 12.10.2 Pique Therapeutics Business Overview
- 12.10.3 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.10.5 Pique Therapeutics Recent Developments
- 12.11 Regeneus
- 12.11.1 Regeneus Company Information
- 12.11.2 Regeneus Business Overview
- 12.11.3 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.11.5 Regeneus Recent Developments
- 12.12 Tessa Therapeutics
- 12.12.1 Tessa Therapeutics Company Information
- 12.12.2 Tessa Therapeutics Business Overview
- 12.12.3 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.12.5 Tessa Therapeutics Recent Developments
- 12.13 Vaccinogen
- 12.13.1 Vaccinogen Company Information
- 12.13.2 Vaccinogen Business Overview
- 12.13.3 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.13.5 Vaccinogen Recent Developments
- 12.14 XEME Biopharma
- 12.14.1 XEME Biopharma Company Information
- 12.14.2 XEME Biopharma Business Overview
- 12.14.3 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2021-2026)
- 12.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
- 12.14.5 XEME Biopharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst